3rd quarter global net revenue of approximately US460 $1,000,000 was achieved by Roche, resulting in royalty revenue of US61 $1,000,000 for PTC. Non GAAP R and D expense was €152,000,000 for the Q3 of 2024, excluding €9,000,000 in non cash stock based compensation expense compared to €150,000,000 for the Q3 of 2023, excluding €14,000,000 in non cash stock based compensation expense. Non GAAP SG and A expense was €63,000,000 for the Q3 of 2024, excluding €10,000,000 in non cash stock based compensation expense, compared to €68,000,000 for the Q3 of 2023, excluding €13,000,000 in non cash stock based compensation expense. Cash, cash equivalents and marketable securities totaled €1,000,000,000 as of September 30, 2024, compared to €877,000,000 as of December 31, 2023. Our strong financial position provides PTC with the necessary resources to execute on our strategy and achieve our milestones over the next several years, including the anticipated launch of ceptiaparin and other products.